Clinical Trials
18 trialsNCT06770582 2026-06-03
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07000084 2026-06-02
GAIN-BCG
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06388720 2026-05-29
IMGeS
National Cancer Center, Korea
Phase 2 Recruiting
NCT07129993 2026-05-14
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo
Phase 2/3 Recruiting
NCT07106762 2026-05-12
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT07566156 2026-05-11
EV-309
Astellas Pharma Inc
Phase 3 Recruiting
NCT06822010 2026-05-06
SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT07097142 2026-05-04
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology
Phase 3 Recruiting
NCT06960577 2026-04-23
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca
Phase 3 Recruiting
NCT03317158 2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT06704191 2026-03-30
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
Phase 1/2 Recruiting
NCT06488222 2026-03-11
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
University of Florida
Phase 2 Recruiting
NCT05644041 2026-02-27
Intravesical Gem/Doce in Patients With NMIBC
University of Arizona
Phase 2 Recruiting
NCT06571708 2025-09-02
NeoSTOP-IT
Columbia University
Phase 2 Recruiting
NCT04574960 2025-07-20
NAUTICAL
University Health Network, Toronto
Phase 3 Recruiting
NCT05024734 2025-03-11
GAIN INST
Hospital Centre Biel/Bienne
Phase 2 Recruiting
NCT04861584 2024-12-04
Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects
Zhujiang Hospital
Phase 2 Recruiting
NCT05531123 2024-07-12
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer
Fudan University
Phase 2 Recruiting